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Aim: To explore the influence of clinical exercise trial participation on glycaemia and
insulin therapy use in adults with type 1 diabetes (T1D).
Research Design and Methods: This study involved a secondary analysis of data
collected from 16 individuals with T1D who completed a randomized clinical trial
consisting of 23-h in-patient phases with a 45-min evening bout of moderate intensity
continuous exercise. Participants were switched from their usual basal-bolus therapy to
ultra-long acting insulin degludec and rapid-acting insulin aspart as well as provided with
unblinded interstitial flash-glucose monitoring systems. To assess the impact of clinical
trial participation, weekly data obtained at the screening visit (pre-study involvement) were
compared against those collated on the last experimental visit (post-study involvement).
Interstitial glucose [iG] data were split into distinct glycaemic ranges and stratified into day
(06:00–23:59) and night (00:00–05:59) time periods. A p-value of ≤ 0.05 was accepted
for significance.
Results: Following study completion, there were significant decreases in both the mean
nocturnal iG concentration (1-0.9 ± 4.5 mmol.L−1, p < 0.001) and the time spent in
severe hyperglycaemia (1-7.2 ± 9.8%, p = 0.028) during the night-time period. The
total daily (1-7.3 ± 8.4 IU, p = 0.003) and basal only (1-2.3 ± 3.8 IU, p = 0.033) insulin
dose requirements were reduced over the course of study involvement.
Conclusions: Participation in clinical research may foster improved nocturnal glycaemia
and reduced insulin therapy use in people with T1D. Recognition of these outcomes
may help encourage volunteers to partake in clinical research opportunities for improved
diabetes-related health outcomes.
Clinical Trial Registration: DRKS.de; DRKS00013509.
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INTRODUCTION
Volunteering as a research participant displays altruism and a
willingness to help advance medical science. However, research
trial participation often requires unaccustomed adjustments
to routine care, as well as considerable time commitments
for those involved. As such, patient enrollment, and indeed
retention, represent long-standing obstacles in the conduction of
clinical research (1–3). Nevertheless, research participation can
provide patients access opportunities to novel pharmacological
therapies and/or technological devices, as well as intense
and frequent interactions with clinical research teams who
provide educational support. For individuals with type 1
diabetes (T1D), pharmaceutical developments in modern ultra-
long acting basal insulins with refined pharmacokinetic and
pharmacodynamic profiles have led to improved glycaemic
outcomes (4–10). Furthermore, recent advances in interstitial
glucose (iG) monitoring systems have challenged the sole
dependency on self-monitoring of blood glucose, and proven
useful in aiding patient adherence to frequent glycaemic
assessment (11–14). In addition, interactive opportunities with
health care professionals who offer medical information and
support can foster positive psychosocial and glycaemic outcomes
(15–17). These pharmaceutical, technological, and physiological
aids are complemented by lifestyle factors, including both diet
and physical activity. Though exercise is endorsed by several
international consensus panels as an integral component of the
treatment plan of those with T1D (18–21), participation rates
remain low, with fears around loss of glycaemic control and
uncertainty in how to appropriately adjust exogenous insulin
therapy cited as leading factors dissuading regular engagement
(22). The heightened bioenergetic demands of exercising muscle
can induce increases in intramuscular glucose uptake by up
to 50-fold that of basal rates (23, 24). When combined with
an inability to lower exogenous insulin concentrations as well
as an often blunted glucoregulatory rescue system (25), the
maintenance of normoglycaemia during exercise is challenging
for those with T1D. Though acutely apparent, the metabolic
challenges evoked by physical exercise may persist for several
hours subsequent to its cessation (26–29). This often extends the
risk of dysglycaemia leading into and throughout the nocturnal
period, at a time when self-monitoring of blood glucose is
inherently difficult. As such, glycaemic management strategies
that seek to address these concerns are integral in encouraging
safe exercise performance whilst minimizing the extent of
glycaemic fluctuations. The ideal therapeutic care of those with
T1D involves a multimodal approach including access to current
pharmacological, technological, and support opportunities that
collectively help to cultivate optimal self-management. Thus,
research trials that include any of these elements may have
clinically relevant outcomes beyond the those solely pertinent to
answering the primary outcome.
Aim
To explore the influence of clinical exercise trial participation on




This study was a secondary analysis of data collected from a
single-centered, randomized, open-label, four-period, cross-over
clinical trial (DRKS.de; DRKS00013509) consisting of four 23-h
in-patient phases with a 45-min evening bout of semi-recumbent
cycling at 60 ± 6% VO2max. The study was performed in
accordance with good clinical practice and the Declaration of
Helsinki (https://www.wma.net/policies-post/wma-declaration
-of-helsinki-ethical-principles-for-medical-research-involving-
human-subjects/). Approval was granted by both the national
research ethics committee (16/WA/0394) and the local health
authority (EudraCT number: 2017-004774-34; UTN: U1111-
1174-6676). The primary outcome was to detail the extent
and prevalence of post-exercise and nocturnal hypoglycaemia
following peri-exercise bolus insulin dose adjustments in
individuals with T1D using multiple daily injections of insulins
aspart (IAsp) and degludec (IDeg). As part of a secondary,
retrospective analysis, the present study sought to explore the
influence of clinical exercise trial participation on glycaemia and
insulin therapy use in adults with T1D.
Screening Visit
Ahead of trial inclusion, participants were screened for
anthropometric, cardiovascular, and T1D specific markers prior
to the performance of a cardio-pulmonary exercise test on a
semi-recumbent cycle ergometer (Corival Recumbent, Lode, NL)
(30). Main inclusion criteria were: diagnosis of T1D for ≥12
months; age 18–65 years (both inclusive); body mass index
of 18.0–29.4 kg.m2; use of multiple daily injections of insulin
for ≥12 months; body mass-specific peak oxygen uptake of
≥20mL.kg−1.min−1, and a status of being physically active as
assessed by the International Physical Activity Questionnaire
Short Form. All participants were considered hypoglycaemic
aware, having avoided recurrent severe hypoglycaemia (defined
as >1 severe hypoglycaemia event during the previous 12
months) and demonstrated a sound understanding of the
symptomatic traits of hypoglycaemia to the investigator. After
successful completion against the reference inclusion criteria,
participants were switched from their usual basal/bolus insulin
therapies (n = 8; glargineU100/IAsp, n = 1; glargineU300/IAsp,
n = 1; IDeg/IAsp, n = 6; detemir/IAsp) to ultra-long-
acting IDeg (Tresiba R©, NovoNordisk, Denmark) in 3mL pre-
filled investigational pens (PDS290) and rapid-acting IAsp
(NovoRapid R© NovoNordisk, Denmark) in 3mL pre-filled
investigational pens (FlexPen R©). Therapy with IDeg began on the
morning following trial inclusion with a starting dosage of 70–
80% of total daily basal insulin dose (TDBD) calculated by means
of a titration algorithm. Participants were required to achieve
a mean overnight-fasted morning blood glucose (BG) value of
4.4–7.2 mmol.L−1 over 3 consecutive days within 4 weeks of
the first basal insulin dose. If glycaemic instability persisted
for ≥3 days following titration, a dose adjustment alteration
was made until criteria was met. A run-in period of >7 days
was required to assure optimal adaptation to IDeg prior to the
experimental period.
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Unblinded flash glucose monitoring readers and sensors
(Freestyle R© Libre, Abbott, Lake Bluff, Illinois, USA) were
provided by the study site for the duration of the trial. The
sensor was inserted into the posterior aspect of the upper arm
and measured interstitial glucose (iG) in 15-minute intervals.
Participants were trained in use of the system and asked to change
the sensor at least 48 h before each trial visit to avoid sensor
expiration during the research period. With the exception of
one individual, all participants were new to use of interstitial
glucose monitoring, having previously used a range of point
of care self-blood glucose monitoring systems. Though familiar
with carbohydrate counting and insulin: carbohydrate dosing
ratios, participants were guided through how to accurately
record dietary information and shown insulin dose adjustment
algorithms by the research team. This included the calculation
of their individualized carbohydrate ([CarbF] = 5.7∗kg/total
daily dose of insulin [TDD]) and correction ([CorrF] = 109
mmol/l/TDD) factors as previously described (31). For the
remainder of their involvement, participants were monitored
by the study personnel to ensure glycaemic stability prior to
each experimental visit. Stability was assessed via inspection of
their iG patterns with particular scrutiny in the avoidance of
hypoglycaemia (≤3.9 mmol.L−1) prior to laboratory attendance.
As to control for any potential influence of extraneous variables
on experimental trial day activities, participants were asked to
replicate their habitual diet, physical activity, and insulin dosing
strategies in the 24 h prior to each laboratory visit. Participants
were contacted frequently by the research team to provide details
of any adjustments.
Experimental Visits
Following preliminary testing (visit 1) and a run-in period for
adjustment to IDeg, visits 2, 3, 4, and 5 were experimental visits
that involved 23-h of in-patient monitoring with an overnight
stay in a clinical research facility. After a standardized day-time
period (08:00–15:59), participants undertook a bout of evening
(17:00) cycling exercise at 60 ± 6 % V̇O2max One hour prior
to, and following exercise, participants administered either a
full (100%) or reduced (50%) dose (100%; 5.1 ± 2.4 vs. 50%;
2.6 ± 1.2 IU, p < 0.001) of individualized IAsp alongside the
consumption identical low-glycaemic index carbohydrate (CHO)
rich meals (1.0 g.CHO.kg−1). An unaltered and regular dose of
IDeg was kept consisted across each experimental visit. Trial day
glycaemia was determined via capillary (08:00–15:59), venous
(16:00–07:00), and interstitial (08:00–07:00) glucose monitoring
over the 23-h in-patient stays.
Pre vs. Post Study Data Analysis
Methodology and Statistical Analysis
Over the course of the study it became apparent that many
individuals were perceiving their participation experience as
beneficial to aspects of their diabetes related care outside of
the experimental periods. Thus, as part of a retrospective,
observational, secondary analysis we investigated weekly data
taken from a “pre-study” period and compared them against data
taken in the final week of their enrolment i.e., “post-study.” The
pre-study period was classified as the 6-days after the screening
visit but before any experimental trial visits (between visits 1
and 2), whilst the post-study period was classified as the 6-days
prior to the final experimental trial visit immediately ahead of
study completion (between visits 4 and 5). A 6-, rather than
7-day average was taken to avoid any potential interference of
trial-related activities on habitual behaviors. Figure 1 provides
a schematic overview of the study design with reference to
the primary interventional manipulations and experimental
visit schedule.
On trial days, participants intake weighed whilst fasted
and asked to report their previous 6-day average basal and
bolus insulin doses, CHO intake and physical activity patterns
(International Physical Activity Questionnaire). iG data were
stratified into time spent within glycaemic thresholds i.e., time
in range (TIR), time below range (TBR) and time above range
(TAR). The targets are further bracketed into levels 1 and 2 to
detail the severity of both hypo-and hyper-glycaemia; TBR 2
(<3.0 mmol.L−1), TBR 1 (≥3.0–<3.9 mmol.L−1), TIR (≥3.9–
≤10.0 mmol.L−1), TAR 1 (≥10.1–≤13.9 mmol.L−1), TAR 2
(>13.9 mmol.L−1) (32). iG data were also split into day (06:00–
23:59) and night (00:00–05:59) time periods. Due to a significant
loss of data points, four participants were excluded from iG
analysis. The significance of change in measurements from pre-
to post-study was assessed via paired student’s t-test or non-
parametric equivalents used when necessary. SPSS (version 26.0)
was used for all data analyses and reporting. P values of a p≤ 0.05
(two-sided) accepted as statistically significant.
RESULTS
Participant Characteristics
Baseline characteristics of study participants are included in
Table 1. The average length of time for trial participation was 55
± 29 days.
Interstitial Glucose Outcomes
Device coverage was ≥89% over the 6-day data capture in
both the pre- and post-study phases (pre; 91 ± 19 vs. post;
89 ± 14%, p = 0.716). Overall and stratified iG are presented
in Table 2. Analysis revealed significant decreases in both the
mean nocturnal iG concentration (1-0.9 ± 4.5 mmol.L−1, p <
0.001) and the TAR2 (1-7.2 ± 9.8%, p = 0.028) during the
night-time hours.
Anthropometry and Insulin Therapy
Outcomes
There were significant reductions in both the total daily (1-7.3±
8.4 IU, p = 0.003) and basal only (1-2.3 ± 3.8 IU, p = 0.033)
insulin dose requirements from pre-to-post-study involvement
(Table 3). There were no changes in any of the anthropometric,
dietary CHO or physical activity metrics.
DISCUSSION
This exploratory study investigated the wider glycaemic
impact of participation in a clinical exercise trial involving
a therapeutic switch to ultra-long acting insulin degludec as
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FIGURE 1 | Schematic overview of the trial design with reference to the four interventional cross over arms involving peri-exercise adjustments to bolus insulin aspart
on a stable background of insulin degludec. IAsp, insulin aspart; IDeg, insulin degludec.
TABLE 1 | Baseline characteristics of study participants.
Baseline characteristics of study participants
Characteristic n = 16
Gender M vs. F (n) 13 vs. 3
Age (years) 34.5 ± 13.9
BMI (kg/m2 ) 26.0 ± 3.4
Lean mass (%) 23.4 ± 3.3
HbA1c (%) 7.2 ± 1.3
HbA1c (mmol/mol) 56 ± 15
Diabetes duration (years) 14.4 ± 11.1
Pre study TDD (IU) 51.7 ± 26.6
Pre study TDBD (IU) 31.3 ± 21.3
V̇O2max (ml.kg
−1.min.−1 ) 40.3 ± 10.3
Data are presented as mean ± SD. n, number of participants.
M, Male; F, Female; BMI, body mass index; Kg, kilograms; M, meters; TDD, Total daily
insulin dose (inclusive of basal and bolus amounts); TDBD, total daily basal insulin dose;
Bm, body mass; ml, millimeters; Min, minutes.
well as the introduction to, and ad-hoc education support
with, an interstitial glucose monitoring system in individuals
with T1D.
Comparative analysis of interstitial glucose (iG) data obtained
over a 6-day period taken before vs. after clinical trial
participation revealed significant reductions in both the mean
nocturnal glucose concentration and the amount of time spent in
severe hyperglycaemia during the night-time hours. Additionally,
upon trial completion, substantial reductions in both total daily,
and basal only, insulin dose requirements were noted in the
absence of changes in any anthropometric, dietary, and physical
activity factors.
The reduction in insulin dosing requirements in the present
study aligns with previous investigations that have demonstrated
the efficacy of IDeg therapy in maintaining glycaemic outcomes
at significantly lower dosing amounts (33, 34). The end of
study IDeg dosing quantities used in this study are similar
to those reported in recent work by Heise et al. (9) (Heise;
0.38 ± 0.23 IU.kg−1 vs. Our data; 0.34 ± 0.20 IU.kg−1),
TABLE 2 | Time spent in each glycaemic range as part of a 6-day analysis from
the first to last experimental trial visits.
Parameter Pre-study Post-study P-value
Overall glucose (mmol.L−1 ) 9.23 ± 4.38 9.07 ± 4.30 0.355
Standard deviation (mmol.L−1 ) 3.83 ± 0.91 3.84 ± 1.02 0.965
CoV (%) 40.99 ± 4.42 42.21 ± 7.37 0.598
Stratified (24h)
Overall TBR2 (%) 2.83 ± 3.91 3.84 ± 2.29 0.246
Overall TBR1 (%) 3.97 ± 1.90 4.00 ± 3.08 0.971
Overall TIR (%) 55.28 ± 18.80 55.26 ± 13.99 0.995
Overall TAR1 (%) 22.15 ± 8.33 23.87 ± 9.82 0.571
Overall TAR2 (%) 15.77 ± 14.74 13.02 ± 10.55 0.391
Stratified Day; 06:00–23:59 vs. Night; 00:00–05:59
Day glucose (mmol.L−1 ) 9.03 ± 4.38 9.15 ± 4.18 0.270
Day TBR2 (%) 2.55 ± 4.35 3.25 ± 3.08 0.495
Day TBR1 (%) 4.58 ± 2.02 4.20 ± 3.64 0.701
Day TIR (%) 57.06 ± 19.59 56.79 ± 14.62 0.954
Day TAR1 (%) 21.60 ± 8.16 23.19 ± 9.31 0.589
Day TAR2 (%) 14.22 ± 14.18 12.57 ± 10.26 0.662
Night glucose (mmol.L−1 ) 9.84 ± 4.52 8.98 ± 4.48 <0.001*
Night TBR2 (%) 3.23 ± 5.64 5.13 ± 5.31 0.138
Night TBR1 (%) 2.00 ± 3.10 3.43 ± 3.62 0.367
Night TIR (%) 50.06 ± 21.18 52.06 ± 16.56 0.673
Night TAR1 (%) 24.22 ± 14.30 26.02 ± 11.57 0.748
Night TAR2 (%) 20.54 ± 18.65 13.35 ± 16.63 0.028*
CoV, coefficient of variation; TBR 2, time below range level 2 (<3.0 mmol.L−1 ); TBR 1, time
below range level 1 (≥3.0–<3.9 mmol.L−1 ); TIR, time in range (≥3.9–≤10.0 mmol.L−1 );
TAR 1, time above range level 1 (≥10.1–≤13.9mmol.L−1 ); TAR 2, time above range level 2
(>13.9 mmol.L−1 ). *p ≤ 0.05 between first pre- and post-study values. Data are reported
as mean ± SD. n =12.
which reaffirms the safe integration of IDeg as a stable
basal therapy at clinically relevant dosing levels. These dose
reductions occurred in the absence of any changes in body mass,
carbohydrate intake and physical activity patterns. Though we
cannot out rule the possibility that great diligence to dietary
tracking may have triggered individuals to select healthier
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TABLE 3 | Participant insulin regime, anthropometric data, and physical activity
patterns on the first vs. last trial visits.
Weekly data from pre-to post-study involvement
Parameter Pre-study Post-study P-value
TDD (IU) 51.7 ± 26.6 44.4 ± 20.7 0.003*
TDBD (IU) 31.3 ± 21.3 29.0 ± 18.4 0.033*
Body mass (kg) 80.0 ± 9.9 80.1 ± 9.6 0.785
CHO intake (g) 194.2 ± 58.0 190.8 ± 64.5 0.666
Physical activity (METs) 3600.3 ± 2943.7 3359.7 ± 2491.9 0.678
TDD, Total daily insulin dose (inclusive of basal and bolus); TDBD, Total daily basal insulin
dose; IU, International units; CHO, carbohydrates; METs, metabolic equivalents. *p≤ 0.05
between pre- and post-study values. Data are presented as mean ± SD.
food options, including lower glycaemic index carbohydrates,
which may have contributed to drop in insulin dose, in light
of the potential obesogenic implications associated with an
over reliance on exogenous insulin administration (35), the
dose reductions observed in this study carry important clinical
undertones that stretch beyond those relating to dysglycaemia.
Furthermore, 14/15 (93%) participants opted for continued
use of IDeg as their basal analog and applied locally for
continued Freestyle Libre provision upon study completion,
perhaps emphasizing the value of these therapeutics in terms of
patient satisfaction.
The significant decreases in both mean iG concentrations and
the amount of TAR2 during nocturnal hours are meaningful
from both a practitioner and patient point of view. Given
the lack of endogenous autoregulation in the synthesis and
secretion of insulin, the prevalence of the dawn phenomenon
is a common feature of T1D which continues to represent
a serious clinical concern (36). Combined with the inherent
difficulties of performing regular self-monitoring of blood
glucose during sleep, dysglycaemia during the night-time
constitutes a major worry not only for those with T1D, but
also for those who take an active role in their care (37–
39). These fears are perhaps magnified following evening
exercise, which, due to its long-lasting insulin-sensitizing effects,
can disrupt glycaemia for the many hours subsequent to
its performance (29, 40–42). Several international panels of
diabetes specialists have convened to outline the merits of
utilizing iG metrics to support decision making in clinical
care (32, 43). The improvements in nocturnal glycaemia
observed in this study may be the result of the introductory
provision of an iG monitoring device, which allowed for the
assessment of glycaemic patterns throughout the night-time
period and hence, the ability to act accordingly to prevent
glycaemic excursions. These results offer encouragement for
the integration of modern ultra-long acting insulin analogs
alongside iG monitoring systems in aiding glucose management
around physical exercise in those with T1D. An important
caveat is that our study cohort had a relatively long diabetes
duration (∼14 years), thus may have had greater experience in
glycaemic management around physical exercise than those with
a newer diagnosis.
For those with T1D, the fear of hypoglycaemia around
exercise prevails as the main barrier to regular engagement,
whilst a greater knowledge of insulin pharmacokinetics
and/or using appropriate approaches to minimize exercise-
related hypoglycaemia are associated with fewer perceived
hurdles (22). The volatility in blood glucose levels
around exercise may be one of the reasons that >60%
of individuals with T1D currently fail to meet physical
activity guidelines (44). To that end it is encouraging to
learn of the potential value interactions with health care
professionals and exercise physiologists throughout trial
participation may have on the individuals involved, who’s
willingness to participate in clinical trials help advance our
research efforts.
Due to the provision of two therapeutic aids alongside
access to clinical diabetes care and support, it is difficult
to discern the exact source of the observed improvements.
Rather, we put forth these findings as part of a multi-
faceted analysis, that, irrespective of being able to irrefutably
demonstrate a clear cause and effect relationship, highlights
the beneficial effects of research participation in a mutually
reciprocal manner. Recognition of these outcomes may help
incite volunteers to partake in clinical trials as well as
encourage scientists to explore hypotheses outside of the
primary objective.
CONCLUSION
Participation in clinical research may foster improved nocturnal
glycaemia and reduced insulin therapy use in people with T1D.
Beyond pursuing the primary outcomes of a research hypothesis,
these data provide a basis for exploring the wider, clinically
relevant health outcomes that may be associated with research
trial participation.
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